FY2028 EPS Forecast for Gossamer Bio Decreased by Analyst

Gossamer Bio, Inc. (NASDAQ:GOSS) – Investment analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of Gossamer Bio in a report released on Tuesday, March 18th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of $0.24 for the year, down from their prior estimate of $0.28. HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.55 EPS.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million.

Separately, Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Gossamer Bio in a report on Friday, March 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Stock Performance

Shares of NASDAQ GOSS opened at $1.36 on Wednesday. The firm’s 50-day moving average price is $1.15 and its 200-day moving average price is $0.98. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.55. The company has a market cap of $308.18 million, a PE ratio of -4.25 and a beta of 1.86. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors have recently made changes to their positions in GOSS. Graham Capital Management L.P. purchased a new stake in Gossamer Bio during the fourth quarter valued at approximately $32,000. US Bancorp DE bought a new stake in shares of Gossamer Bio during the 3rd quarter valued at $39,000. Fullcircle Wealth LLC purchased a new stake in shares of Gossamer Bio in the 4th quarter worth $43,000. GSA Capital Partners LLP purchased a new stake in shares of Gossamer Bio in the 3rd quarter worth $67,000. Finally, Velan Capital Investment Management LP bought a new position in Gossamer Bio in the 4th quarter worth $68,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.